by Kai Herdin | Sep 12, 2025 | News
NADMED has been selected to join the prestigious AMPlify program, a U.S. market entry initiative jointly organized by Mayo Clinic and Business Finland. The program combines world-class clinical expertise, valuable market knowledge, and extensive networks to support...
by Kai Herdin | Mar 4, 2025 | News
Affinity Biomarker Labs, based in London, UK, is the latest partner to join the NADMED network, offering NAD+ and NADH testing upon request. Established in 2017 at Imperial College London’s White City Campus, Affinity Biomarker Labs was founded by a team of clinical...
by Kai Herdin | Dec 13, 2024 | News
Research and Markets, one of the world’s leading market research firms, has identified NADMED as one of the fastest-growing clinical laboratory tests in Europe over the next five years. The molecular diagnostics segment, a key area of focus, is projected to achieve a...
by Kai Herdin | Aug 22, 2024 | News
The investment round was led by Finnish science-based startup investor Nordic Science Investments (NSI). Additional funding was secured from previous investors Voima Ventures and University of Helsinki Funds, from a number of private European investors, and a grant...